- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05872282
Percutaneous Endovascular Arch Repair Trial (PEART) Study
December 25, 2023 updated by: Hangzhou Endonom Medtech Co., Ltd.
Feasible Study on a New Technique of ZIPPER Aortic Arch Stentgraft System in the Treatment of Aortic Arch Disease
This study is the feasible study on a new technique of ZIPPER aortic arch stentgraft system
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The feasible study of ZIPPER aortic arch stentgraft system is a prospective, multicenter, single arm trial, which will enroll a total of 24 patients.
The goal of this study is to evaluate the safety and efficacy of ZIPPER aortic arch stentgraft system in the treatment of patients with aortic arch disease, included aortic arch dissections, aneurysms, residual dissection following ascending aorta surgical operation.
Study Type
Interventional
Enrollment (Estimated)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Weiguo Fu
- Phone Number: 13801760929
- Email: fu.weiguo@zs-hospital.sh.cn
Study Contact Backup
- Name: Wayne W. Zhang
- Email: wwzhang08@gmail.com
Study Locations
-
-
-
Chengdu, China
- Not yet recruiting
- Jia Hu
-
Contact:
- Jia Hu
- Email: 1725194@qq.com
-
Shanghai, China
- Recruiting
- Weiguo Fu
-
Contact:
- Weiguo Fu
- Email: fu.weiguo@zs-hospital.sh.cn
-
Taiyuan, China
- Recruiting
- Honglin Dong
-
Contact:
- Honglin Dong
- Email: honglindong@sxmu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients aged 18 to 80 years old
- Patients diagnosed with aortic arch disease requiring intervention, including non-A-non-B aortic dissection, or residual dissection after type A ascending aortic repair; aortic arch aneurysms.
Patients with suitable vascular conditions, including:
- Ascending aorta (including surgical graft) length greater than 30 mm (from the aortic sinusoid junction to the proximal cardiac margin of the innominate artery).
- Proximal anchoring zone diameter ≥ 24 mm and ≤ 47 mm;
- Proximal anchoring zone length ≥ 20 mm;
- Innominate artery, left common carotid artery and left subclavian artery diameter ≤ 24 mm and ≥ 7 mm, length ≥ 20 mm;
- Suitable arterial access for endovascular interventional treatment;
- Patients able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the subject him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol.
- Evaluated by at least two investigators that the subjects are high-risk patients with more complications, poor general condition, high risk of deep hypothermic circulatory arrest, and not suitable for total arch replacement and other surgical procedures.
Exclusion Criteria:
- Previously received open surgery or endovascular intervention for descending aorta or abdominal aorta;
- Infectious aortic disease, takayasu arteritis, Marfan syndrome (or other connective tissue diseases );
- Patients that have experienced systemic infection within past three months;
- Neck surgery was performed within past three months;
- Patients with severe stenosis, calcification, thrombosis or tortuosity in the brachiocephalic trunk, left common carotid artery or left subclavian artery;
- Patients with intestinal necrosis and lower limb ischemic necrosis;
- Paraplegic patients;
- Heart transplant patients;
- Patients that have suffered MI or stroke within past three months;
- Patients with Class IV heart function (NYHA classification) or LVEF<30%
- Active peptic ulcers or upper gastrointestinal bleeding occurring within the past three months;
- Hematological abnormality, defined as follows: Leukopenia (WBC < 3 × 109/L), anemia (Hb < 90 g/L); coagulation dysfunction, thrombocytopenia (PLT count< 50 × 109/L);
- Patients with renal insufficiency, serum creatinine > 150 umol/L (or 3.0 mg/dl) and / or end-stage renal disease requiring dialysis, shall be determined by the investigator after a comprehensive analysis;
- Patients with severe liver dysfunction: ALT or AST exceeding 3 times the upper limit of norma, serum total bilirubin (STB) exceeds 2 times the upper limit of normal;
- Patients who are allergic to contrast agents;
- Patients that are pregnant or breastfeeding;
- Patients with severe comorbidities who cannot tolerate anesthesia and surgery;
- Patients with a life expectancy of less than 12 months;
- Patients currently participating in other drug or device study;
- The investigator assessed that the patient was ineligible for the study for other diseases or abnormalities.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ZIPPER aortic arch stentgraft system
|
The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from major device/procedure-related adverse events within 30 days post-operation.
Time Frame: 30 days after intervention
|
Device or procedure related major adverse events included: stroke, respiratory failure, pericardial tamponade, dissection or aneurysm rupture, paraplegia, stent occlusion, fracture, migration, access vessel thrombosis or rupture, conversion to open surgery, death.
|
30 days after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of severe adverse events.
Time Frame: within 12 months post-intervention
|
Refers to an event that occurs during the clinical trial that results in mortality or serious deterioration in patient health, including a fatal illness or injury, a permanent defect in body structure or body function, or an event that requires medical or surgical intervention to avoid one or more permanent defects in body structure or body function.
|
within 12 months post-intervention
|
Immediate postoperative technical success.
Time Frame: immediately after intervention
|
Immediate technical success is defined as successful delivery of the aortic and branching stent graft conveyors to their predetermined positions, accurate positioning and successful deployment of the stent, safe removal of the delivery device outside the body, absence of Type I and III endoleaks on angiography at the end of the procedure , and patent branch stents.
|
immediately after intervention
|
Incidence of Type I or Type III endoleaks.
Time Frame: 1 month, 6 months and 12 months post-intervention
|
Endoleak evaluated by DSA or CTA during operation and at 1 month, 6 months and 12 months after operation.
Intraoperative endoleaks that were treated with adjuvant therapy were not documented.
Endoleaks occurring in the same subject after completion of the procedure, and that were not treated at different visits, are counted as once.
|
1 month, 6 months and 12 months post-intervention
|
Incidence of aortic arch stent graft migration.
Time Frame: 1 month, 6 months and 12 months post-intervention
|
CTA will be performed at 1, 6, and 12 months after operation to determine if the stent has migrated, and evaluations will be recorded for both the main and branch stents.
Migration is defined as the main and branched stents migrate more than 10 mm at postoperative follow-up compared with that 1 month post-intervention.
|
1 month, 6 months and 12 months post-intervention
|
Postoperative branch vessel patency rate.
Time Frame: 1 month, 6 months and 12 months post-intervention
|
CTA examinations will be performed at 1, 6, and 12 months post-operation to evaluate branch vessel revascularization and whether there is occlusion, stenosis, or stent thrombosis.
|
1 month, 6 months and 12 months post-intervention
|
Results of aortic remodeling after aortic dissection surgery
Time Frame: 1 month, 6 months and 12 months post-intervention
|
CTA examinations will be performed at 1, 6, and 12 months post-operation to evaluate results of aortic remodeling, including the expansion of the true lumen and the thrombosis of the false lumen at the coverage of the aortic dissection vascular stent to determine whether the blood vessel is successfully remodeled.
|
1 month, 6 months and 12 months post-intervention
|
Incidence of surgically induced de novo aortic dissection converted to open-heart surgery or secondary intervention.
Time Frame: within 12 months post-intervention
|
Whether or not the patient experienced surgically induced de novo aortic dissection converted to open-heart surgery or secondary intervention will be determined.
|
within 12 months post-intervention
|
Aortic-related mortality at 12 months post operation.
Time Frame: within 12 months post-intervention
|
Refers to death caused by aortic rupture or endovascular treatment.
|
within 12 months post-intervention
|
All-cause mortality and major stroke within 12 months post-procedure.
Time Frame: within 12 months post-intervention
|
All-cause mortality includes cardiac death, non-cardiac death, and unexpected death.
Major stroke is defined as a modified Rankin score (mRS) ≥ 2 at 90 days after stroke onset.
|
within 12 months post-intervention
|
Incidence of device-related adverse events.
Time Frame: within 12 months post-intervention
|
Device-related adverse event refers to an adverse medical event related to the use of test device during the clinical trial.
However, a distinction should be made with respect to normal postoperative stress response, such as fever and chest and back discomfort, which, in the judgment of the investigator, need not be recorded as an adverse event.
|
within 12 months post-intervention
|
Progression control of aortic aneurysm
Time Frame: 1 month, 6 months and 12 months post-intervention
|
CTA examinations will be performed at 1, 6, and 12 months post-operation to evaluate results of progression control of aortic aneurysm.
The maximum diameter of aortic aneurysm increases by ≤ 5 mm after 12 months of CTA examination compared with that before surgery.
|
1 month, 6 months and 12 months post-intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Weiguo Fu, Fudan University
- Principal Investigator: Wayne W. Zhang, Seattle,Washington,USA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 28, 2023
Primary Completion (Estimated)
April 28, 2025
Study Completion (Estimated)
April 28, 2025
Study Registration Dates
First Submitted
May 9, 2023
First Submitted That Met QC Criteria
May 14, 2023
First Posted (Actual)
May 24, 2023
Study Record Updates
Last Update Posted (Estimated)
January 1, 2024
Last Update Submitted That Met QC Criteria
December 25, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZIPPER V1.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Diseases
-
Cook Research IncorporatedRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch Aneurysm | Complex Abdominal Aortic Aneurysm | Chronic Aortic DissectionDenmark, France, Germany
-
Gustavo OderichWilliam Cook AustraliaRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch Aneurysm | Complex Abdominal Aortic Aneurysm | Aortic Arch DissectionUnited States
-
Baptist Health South FloridaWilliam Cook AustraliaRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch AneurysmUnited States
-
University of California, San DiegoRecruitingJuxtarenal Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm | Pararenal Aortic Aneurysm | Complex Abdominal Aortic AneurysmUnited States
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingThoracoabdominal Aortic AneurysmsChina
-
NYU Langone HealthCompletedThoracoabdominal Aortic AneurysmsUnited States
-
Darren Schneider, M.D.RecruitingEndovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent GraftsAortic Aneurysm, Thoracic | Aortic Aneurysm, Thoracoabdominal | Aortic Dissection, ThoracoabdominalUnited States
-
Assistance Publique Hopitaux De MarseilleCompletedAbdominal Aortic AneurysmsFrance
-
University of South FloridaMedtronic; Sanford HealthActive, not recruiting
-
University of BolognaCompletedThoracoabdominal Aortic Aneurysm | Ruptured Thoracic Aneurysm | Ruptured Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm, RupturedItaly
Clinical Trials on ZIPPER aortic arch stentgraft system
-
University Hospital MuensterRecruitingAortic Arch Aneurysm | Aortic Arch | Dissection of Aortic Arch | Triple BranchGermany
-
University Hospital MuensterRecruitingAortic Aneurysm | Endovascular Aortic Repair | Stent-Graft EndoleakGermany
-
Alder Hey Children's NHS Foundation TrustUnknownCardiac | Infants | Neonates | Aortic Arch Surgery | Brain VascularUnited Kingdom
-
Hangzhou Endonom Medtech Co., Ltd.RecruitingAortic Aneurysm and DissectionChina
-
Chinese Academy of Medical Sciences, Fuwai HospitalPeking University People's Hospital; Beijing Hospital; China-Japan Friendship...UnknownUlcer | Aortic Dissection | Aortic Arch Aneurysm | PseudoaneurysmChina
-
Endospan Ltd.Completed
-
University of North Carolina, Chapel HillCook Group Incorporated; UNC HospitalsEnrolling by invitationAortic Aneurysm, Abdominal | Aortic Arch Aneurysm | Ascending Aorta AneurysmUnited States
-
Darren Schneider, M.D.RecruitingEndovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent GraftsAortic Aneurysm, Thoracic | Aortic Aneurysm, Thoracoabdominal | Aortic Dissection, ThoracoabdominalUnited States
-
Helsinki University Central HospitalAssistance Publique - Hôpitaux de Paris; Universitaire Ziekenhuizen KU Leuven; Azienda Ospedaliera Universitaria Integrata Verona and other collaboratorsActive, not recruitingType A Aortic DissectionSpain, Belgium, Finland, United Kingdom, Germany, Italy, Czechia, France
-
Gustavo OderichWilliam Cook AustraliaRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch Aneurysm | Complex Abdominal Aortic Aneurysm | Aortic Arch DissectionUnited States